▁Sub 10.375
title 8.375
: 4.76171875
▁Ag 8.9609375
gress 2.984375
ive 0.209716796875
▁Mark 6.62109375
eting 1.1455078125
▁Cla 8.0390625
ims 1.5712890625
▁Must 8.25
▁be 2.93359375
▁Sc 8.125
rut 3.037109375
in 0.8779296875
ized 0.343994140625
▁to 5.90234375
▁Ens 7.3359375
ure 0.15478515625
▁Effect 6.60546875
iveness 1.494140625
▁and 3.353515625
▁Pat 7.6953125
ient 0.3701171875
▁Saf 2.052734375
ety 0.08038330078125
<0x0A> 4.65234375
By 4.76953125
▁[ 7.0234375
Your 8.6484375
▁Name 0.359375
] 0.444580078125
<0x0A> 0.81494140625
[ 3.537109375
date 6.9453125
] 0.456298828125
<0x0A> 0.2420654296875
In 3.974609375
▁an 4.05078125
▁industry 5.2109375
▁eager 8.7578125
ly 2.1328125
▁await 0.94482421875
ing 0.0140533447265625
▁ground 9.171875
bre 0.5009765625
aking 0.0006861686706542969
▁adv 2.236328125
anc 0.9521484375
ements 0.00012135505676269531
▁in 0.599609375
▁cancer 3.904296875
▁treatment 1.0771484375
, 0.20263671875
▁a 2.73828125
▁British 7.484375
▁bi 3.83203125
ote 0.1558837890625
ch 0.493408203125
▁company 0.69970703125
▁has 1.345703125
▁recently 2.8125
▁announced 1.4052734375
▁positive 5.421875
▁early 3.876953125
- 2.8125
stage 0.29638671875
▁results 0.7900390625
▁for 1.4560546875
▁their 2.994140625
▁experimental 2.78125
▁cancer 2.220703125
▁drug 1.693359375
, 1.14453125
▁generating 10.296875
▁significant 2.96484375
▁excitement 1.5263671875
▁among 1.5048828125
▁patients 3.150390625
, 1.109375
▁health 3.1640625
care 0.304443359375
▁profession 0.734375
als 5.4001808166503906e-05
, 0.31689453125
▁and 0.1380615234375
▁invest 1.6435546875
ors 0.0189208984375
▁al 0.77685546875
ike 1.9073486328125e-05
. 0.04559326171875
▁Non 8.296875
eth 0.347412109375
eless 9.5367431640625e-05
, 0.006465911865234375
▁industry 5.3828125
▁anal 2.794921875
yst 0.0030612945556640625
s 0.0103607177734375
▁are 1.435546875
▁ur 4.85546875
ging 0.021484375
▁c 6.68359375
aut 0.00072479248046875
ious 0.00882720947265625
▁optim 0.12432861328125
ism 0.0005803108215332031
, 1.154296875
▁stress 5.38671875
ing 0.0016469955444335938
▁the 0.9638671875
▁importance 2.234375
▁of 0.0218048095703125
▁rig 4.8515625
orous 0.064453125
▁scr 7.671875
ut 0.0008296966552734375
iny 0.0034351348876953125
▁to 2.708984375
▁ensure 0.88671875
▁the 1.09375
▁drug 1.2080078125
' 0.48779296875
s 0.0004215240478515625
▁effect 2.251953125
iveness 0.00910186767578125
▁and 0.81640625
▁safety 0.35498046875
▁for 3.408203125
▁patients 0.822265625
. 0.448486328125
<0x0A> 0.1964111328125
The 1.6171875
▁cancer 5.2734375
▁drug 0.2432861328125
, 0.837890625
▁developed 3.642578125
▁by 0.033935546875
▁the 2.32421875
▁British 1.2314453125
▁bi 0.213623046875
ote 0.00385284423828125
ch 0.08526611328125
▁firm 3.025390625
, 1.4814453125
▁has 5.44921875
▁shown 1.794921875
▁encourag 3.28515625
ing 0.00086212158203125
▁signs 2.94921875
▁of 1.419921875
▁effic 1.2470703125
acy 6.4373016357421875e-06
▁in 0.57275390625
▁early 1.55859375
▁clin 1.9462890625
ical 0.0002903938293457031
▁tri 0.1253662109375
als 3.0040740966796875e-05
. 1.353515625
▁Pre 3.9453125
lim 0.036376953125
inary 0.00046372413635253906
▁data 1.9423828125
▁indicates 2.888671875
▁that 0.16259765625
▁it 4.8125
▁effectively 5.0
▁targets 2.21875
▁cancer 1.994140625
▁cells 0.419189453125
, 1.4814453125
▁th 10.0390625
wart 0.50048828125
ing 0.0023822784423828125
▁their 0.89697265625
▁growth 1.6103515625
▁and 0.2412109375
▁pro 4.21484375
l 0.452880859375
ifer 0.0001806020736694336
ation 0.00392913818359375
, 1.1796875
▁and 1.552734375
▁exhib 5.51171875
its 1.4619140625
▁potential 4.67578125
▁as 2.685546875
▁a 0.306640625
▁th 4.4453125
era 7.748603820800781e-05
pe 2.7060508728027344e-05
ut 2.086162567138672e-05
ic 0.0030059814453125
▁break 6.6640625
through 0.002033233642578125
▁in 1.556640625
▁various 8.3203125
▁types 1.0185546875
▁of 0.0158538818359375
▁cancer 0.260986328125
, 1.90234375
▁including 0.5009765625
▁not 8.84375
or 2.416015625
iously 0.00025725364685058594
▁hard 2.693359375
- 0.084228515625
to 0.003902435302734375
- 0.0034351348876953125
tre 0.031646728515625
at 0.0005588531494140625
▁m 4.5390625
align 0.0280303955078125
an 0.050750732421875
cies 3.8743019104003906e-05
. 1.541015625
<0x0A> 0.77783203125
Th 4.08203125
ese 1.3310546875
▁g 7.5625
lim 1.0
ps 1.857421875
es 0.0007104873657226562
▁of 0.0855712890625
▁success 1.7421875
▁have 1.728515625
▁spark 3.30859375
ed 0.00026869773864746094
▁optim 3.4296875
ism 0.01461029052734375
▁for 3.732421875
▁the 0.78857421875
▁development 3.66015625
▁of 0.094482421875
▁a 1.79296875
▁much 4.3828125
- 0.07965087890625
ne 0.09246826171875
eded 8.106231689453125e-05
▁alternative 4.03515625
▁for 2.984375
▁patients 0.84326171875
▁whose 4.28125
▁treatment 2.953125
▁options 0.08831787109375
▁have 1.4677734375
▁been 0.8369140625
▁limited 0.52685546875
. 2.712890625
▁However 1.2978515625
, 0.0011091232299804688
▁anal 3.064453125
yst 0.00110626220703125
s 0.001430511474609375
▁are 1.2060546875
▁rem 4.828125
inding 0.056060791015625
▁the 1.8125
▁medical 3.767578125
▁community 0.2030029296875
▁and 2.236328125
▁invest 0.87548828125
ors 0.0928955078125
▁that 1.26953125
▁ca 3.779296875
ution 0.0009493827819824219
▁must 1.8779296875
▁always 4.8203125
▁accomp 4.28515625
any 1.990795135498047e-05
▁enthus 1.955078125
ias 0.040740966796875
m 6.42538070678711e-05
▁in 2.544921875
▁the 0.783203125
▁field 4.171875
▁of 0.11346435546875
▁experimental 5.98828125
▁dru 1.947265625
gs 4.553794860839844e-05
. 0.93505859375
<0x0A> 0.84912109375
" 2.212890625
Wh 3.140625
ile 0.022735595703125
▁the 1.45703125
▁early 1.5087890625
▁results 0.9716796875
▁are 0.5869140625
▁certainly 3.607421875
▁prom 0.94384765625
ising 0.000152587890625
, 0.134033203125
▁it 1.8955078125
' 1.1533203125
s 0.004062652587890625
▁essential 3.515625
▁to 0.9033203125
▁recognize 3.18359375
▁that 0.1859130859375
▁further 4.375
▁investigation 4.03125
▁and 2.05078125
▁more 5.4609375
▁extensive 2.654296875
▁clin 0.77392578125
ical 0.0006823539733886719
▁tri 0.1839599609375
als 0.00018799304962158203
▁are 0.2027587890625
▁needed 1.263671875
▁to 0.59375
▁fully 2.080078125
▁understand 1.671875
▁the 0.318115234375
▁drug 1.0732421875
' 0.034759521484375
s 0.0005197525024414062
▁effect 1.990234375
iveness 0.031158447265625
, 2.65234375
▁side 2.685546875
▁effects 0.0634765625
, 0.06475830078125
▁and 0.0791015625
▁potential 1.619140625
▁long 2.78515625
- 0.00841522216796875
term 0.0038776397705078125
▁ris 1.8251953125
ks 4.291534423828125e-06
," 0.88232421875
▁says 1.3447265625
▁Dr 1.72265625
. 0.033905029296875
▁Jane 5.93359375
▁Sim 6.265625
m 2.068359375
ons 0.0340576171875
, 0.110107421875
▁a 1.0791015625
▁ren 3.46484375
owned 0.003162384033203125
▁on 0.7978515625
colog 0.10418701171875
ist 0.00775909423828125
▁from 3.93359375
▁a 3.990234375
▁pr 3.169921875
estig 2.8014183044433594e-05
ious 0.00017344951629638672
▁medical 1.2705078125
▁inst 4.46484375
itute 0.00225830078125
. 0.86279296875
<0x0A> 1.2783203125
Anal 3.38671875
yst 0.00955963134765625
s 0.012664794921875
▁cont 6.76171875
end 0.0114593505859375
▁that 0.056182861328125
▁companies 6.96484375
▁in 3.56640625
▁the 0.162109375
▁bi 1.859375
ote 0.06683349609375
ch 0.1806640625
▁space 2.53515625
▁often 3.361328125
▁face 2.974609375
▁immense 5.390625
▁pressure 0.6650390625
▁– 7.8828125
▁both 1.2470703125
▁internal 2.537109375
▁and 0.027191162109375
▁external 0.053192138671875
▁– 0.06207275390625
▁to 0.041259765625
▁present 5.40625
▁their 3.572265625
▁dru 2.35546875
gs 1.2993812561035156e-05
▁as 1.2783203125
▁ground 5.078125
break 5.9921875
ers 0.015594482421875
, 1.0986328125
▁creating 5.80859375
▁an 1.8583984375
▁atmosphere 2.533203125
▁of 0.552734375
▁elev 7.9296875
ated 0.003841400146484375
▁expect 0.29052734375
ations 0.0017948150634765625
. 1.4658203125
▁Sub 8.7578125
sequently 0.377197265625
, 0.0032939910888671875
▁invest 3.69140625
ors 0.08660888671875
▁may 3.04296875
▁h 8.640625
inge 2.09765625
▁their 0.2364501953125
▁hopes 2.796875
▁on 0.427734375
▁early 2.662109375
- 1.6708984375
stage 0.058685302734375
▁data 2.568359375
▁that 2.05078125
▁is 2.31640625
▁yet 3.859375
▁to 0.050689697265625
▁be 0.205322265625
▁valid 2.767578125
ated 0.0002663135528564453
▁by 1.01953125
▁larger 2.466796875
, 1.53125
▁more 0.2452392578125
▁compreh 1.546875
ensive 0.0003097057342529297
▁tri 1.2607421875
als 5.614757537841797e-05
. 0.343994140625
▁Several 9.328125
▁previous 5.78125
▁instances 3.841796875
▁have 1.052734375
▁demonstrated 1.67578125
▁the 0.82958984375
▁per 3.2421875
ils 0.262451171875
▁of 0.10614013671875
▁over 2.931640625
h 2.361328125
yp 0.435791015625
ing 0.15576171875
▁dru 3.1953125
gs 0.000125885009765625
▁prem 7.99609375
ature 0.00921630859375
ly 0.0007052421569824219
, 0.61328125
▁leading 1.880859375
▁to 0.06219482421875
▁dashed 7.3046875
▁hopes 0.80517578125
, 2.015625
▁was 4.10546875
ted 0.018402099609375
▁resources 0.94580078125
, 0.041839599609375
▁and 0.028106689453125
▁patient 5.3359375
▁disappoint 2.044921875
ment 0.027252197265625
. 0.0662841796875
<0x0A> 0.10589599609375
Dr 3.1171875
. 0.0173187255859375
▁David 6.53515625
▁Thompson 6.69921875
, 0.07122802734375
▁a 0.58203125
▁regul 8.546875
atory 0.00150299072265625
▁expert 1.140625
, 1.5849609375
▁acknowled 4.77734375
ges 0.185546875
▁the 0.650390625
▁need 2.521484375
▁for 0.2303466796875
▁optim 6.421875
ism 0.04248046875
▁while 4.875
▁ca 1.685546875
ution 0.00711822509765625
ing 0.07159423828125
▁against 0.60888671875
▁un 3.80859375
checked 6.06640625
▁enthus 0.8525390625
ias 0.0010614395141601562
m 4.601478576660156e-05
. 0.434326171875
▁" 0.393798828125
It 2.029296875
' 0.301513671875
s 0.000820159912109375
▁essential 1.90234375
▁for 2.19921875
▁the 1.986328125
▁public 4.0078125
, 2.431640625
▁regul 3.328125
ators 0.23193359375
, 0.035491943359375
▁and 0.1842041015625
▁health 3.2890625
care 0.149658203125
▁profession 0.464599609375
als 0.00024700164794921875
▁to 0.2169189453125
▁crit 6.9296875
ically 9.131431579589844e-05
▁evaluate 1.3271484375
▁the 0.6708984375
▁claims 5.24609375
▁made 1.009765625
▁by 0.427001953125
▁bi 1.5302734375
ote 0.041534423828125
ch 0.2109375
▁companies 0.287353515625
▁and 2.072265625
▁independently 7.75
▁verify 1.8818359375
▁the 0.56298828125
▁data 2.23046875
," 2.4296875
▁he 0.405029296875
▁ca 5.8203125
utions 0.0127410888671875
. 0.035552978515625
▁" 0.8408203125
Bal 9.3125
ancing 1.39453125
▁hope 3.37109375
▁with 0.70703125
▁scientific 6.01171875
ally 5.1171875
▁sound 1.66015625
▁evidence 2.17578125
▁is 0.39892578125
▁critical 2.091796875
▁for 1.9404296875
▁avoid 6.01953125
ing 0.0007958412170410156
▁unnecessary 3.390625
▁set 4.9140625
back 0.0085906982421875
s 0.002834320068359375
▁down 4.34375
▁the 0.00240325927734375
▁line 0.98486328125
." 0.226318359375
<0x0A> 0.03131103515625
Reg 4.73046875
ul 0.412109375
atory 0.2320556640625
▁authorities 2.9296875
, 2.052734375
▁such 1.8095703125
▁as 0.0035572052001953125
▁the 0.06671142578125
▁Food 1.5791015625
▁and 0.04693603515625
▁D 0.0035190582275390625
rug 1.704692840576172e-05
▁Administration 0.00830078125
▁( 0.52685546875
F 0.003147125244140625
DA 0.0003018379211425781
) 1.29296875
▁and 0.439453125
▁the 0.6923828125
▁European 0.91943359375
▁Medic 0.02764892578125
ines 0.0034389495849609375
▁Agency 0.0110321044921875
▁( 0.10894775390625
EMA 0.0084228515625
), 0.143798828125
▁play 3.798828125
▁a 0.364013671875
▁central 4.05859375
▁role 0.0109710693359375
▁in 0.014007568359375
▁ens 1.26171875
uring 3.981590270996094e-05
▁the 1.0703125
▁integrity 2.98046875
▁and 1.6494140625
▁safety 0.9736328125
▁of 0.004459381103515625
▁new 3.181640625
▁drug 3.005859375
▁candidates 1.8740234375
. 0.6162109375
▁As 3.263671875
▁research 7.15234375
▁progress 3.646484375
es 0.0240020751953125
, 0.413818359375
▁it 3.599609375
▁is 1.0029296875
▁cru 2.123046875
cial 0.002704620361328125
▁that 0.900390625
▁these 1.4697265625
▁ag 1.673828125
encies 0.0017070770263671875
▁maintain 2.78125
▁a 1.4130859375
▁watch 2.1796875
ful 0.005748748779296875
▁eye 0.0226898193359375
▁on 1.0673828125
▁the 0.77880859375
▁development 2.02734375
▁process 2.0390625
, 1.3251953125
▁guarantee 6.30859375
ing 0.029815673828125
▁that 0.6826171875
▁the 1.482421875
▁drug 1.3818359375
' 1.8740234375
s 6.365776062011719e-05
▁effic 1.3798828125
acy 2.6941299438476562e-05
▁and 0.363037109375
▁safety 0.1953125
▁profiles 6.64453125
▁align 4.68359375
▁with 0.023162841796875
▁the 1.3232421875
▁highest 5.5859375
▁standards 0.7314453125
. 1.03515625
<0x0A> 0.294921875
More 5.50390625
over 0.50439453125
, 0.00026917457580566406
▁open 9.546875
▁and 1.642578125
▁transparent 0.435791015625
▁communication 0.732421875
▁between 0.50146484375
▁the 1.4365234375
▁bi 2.27734375
ote 0.027801513671875
ch 0.06610107421875
▁firm 1.869140625
▁and 0.7275390625
▁the 1.4619140625
▁wider 5.796875
▁scientific 1.583984375
▁community 0.1448974609375
▁is 0.41748046875
▁essential 0.9052734375
. 2.271484375
▁Re 6.88671875
le 1.5732421875
asing 0.00014066696166992188
▁compreh 5.3671875
ensive 0.005298614501953125
▁data 1.224609375
, 2.736328125
▁including 1.0126953125
▁the 2.64453125
▁drug 3.2109375
' 0.045623779296875
s 0.0018863677978515625
▁mechanism 1.21484375
▁of 0.0210418701171875
▁action 0.003345489501953125
, 0.35546875
▁statistical 7.12109375
▁anal 1.2451171875
ys 1.1324882507324219e-05
es 3.600120544433594e-05
, 0.1741943359375
▁and 0.196044921875
▁potential 3.78125
▁side 0.37890625
▁effects 0.0223541259765625
, 0.183349609375
▁fost 5.3203125
ers 0.006664276123046875
▁an 3.498046875
▁environment 1.302734375
▁of 0.22607421875
▁trust 1.5166015625
, 2.291015625
▁en 2.169921875
abling 0.068359375
▁other 6.125
▁exper 3.693359375
ts 8.296966552734375e-05
▁to 0.54052734375
▁conduct 3.09375
▁peer 4.77734375
▁reviews 1.8955078125
▁and 0.34912109375
▁independent 5.3359375
▁anal 3.064453125
ys 0.00019669532775878906
es 6.67572021484375e-06
▁for 5.78125
▁validation 3.412109375
. 0.611328125
<0x0A> 0.39306640625
U 4.08203125
lt 0.08123779296875
imately 0.0009870529174804688
, 0.0007786750793457031
▁the 1.408203125
▁ar 11.0078125
du 0.0902099609375
ous 0.0011377334594726562
▁journey 2.513671875
▁from 2.1640625
▁prom 5.19140625
ising 0.00031256675720214844
▁early 0.685546875
- 0.5888671875
stage 0.0238189697265625
▁results 1.1494140625
▁to 0.04644775390625
▁a 1.744140625
▁successfully 7.40234375
▁approved 2.46484375
▁cancer 3.44140625
▁treatment 1.2373046875
▁involves 4.85546875
▁multiple 4.30859375
▁stages 2.474609375
▁of 0.54931640625
▁extensive 6.02734375
▁research 1.9990234375
, 0.7861328125
▁scr 2.630859375
ut 0.0003771781921386719
iny 0.0255889892578125
, 0.06878662109375
▁and 0.064208984375
▁collaboration 4.1796875
. 0.80810546875
▁While 2.44921875
▁the 1.517578125
▁British 3.9765625
▁bi 0.1087646484375
ote 0.0005636215209960938
ch 0.00800323486328125
▁company 1.083984375
' 0.99462890625
s 0.0009136199951171875
▁cancer 3.85546875
▁drug 0.11962890625
▁has 1.40234375
▁und 6.68359375
eni 1.5791015625
ably 0.32177734375
▁shown 1.30078125
▁initial 3.650390625
▁promise 0.5078125
, 0.1473388671875
▁anal 3.416015625
yst 0.0003979206085205078
s 0.000751495361328125
▁and 2.5
▁industry 2.4921875
▁exper 0.90966796875
ts 5.364418029785156e-06
▁ca 2.263671875
ution 0.0015239715576171875
▁against 0.71484375
▁und 5.22265625
ue 0.019744873046875
▁ex 5.24609375
uber 0.0174560546875
ance 0.0095062255859375
, 1.7373046875
▁stress 1.25
ing 0.0005445480346679688
▁the 0.06134033203125
▁need 1.513671875
▁for 0.1300048828125
▁thorough 3.701171875
▁scientific 3.810546875
▁evaluation 3.5703125
▁before 2.947265625
▁making 2.91796875
▁le 4.6328125
aps 0.0811767578125
▁of 0.1251220703125
▁faith 0.050445556640625
. 0.70703125
<0x0A> 0.135986328125
As 5.1796875
▁patients 3.90625
, 0.51171875
▁health 0.3447265625
care 0.0156402587890625
▁profession 0.1280517578125
als 1.5020370483398438e-05
, 0.01331329345703125
▁and 0.0247955322265625
▁invest 0.08154296875
ors 0.001605987548828125
▁eager 4.4453125
ly 0.012603759765625
▁anticip 2.6796875
ate 0.0027294158935546875
▁further 3.77734375
▁develop 1.7724609375
ments 0.00022542476654052734
, 0.75390625
▁it 1.3935546875
▁is 0.317626953125
▁vital 2.486328125
▁to 0.951171875
▁recognize 3.611328125
▁the 0.5146484375
▁importance 0.71142578125
▁of 0.00749969482421875
▁maintain 4.24609375
ing 0.00013375282287597656
▁a 0.96875
▁c 2.84765625
aut 0.0013265609741210938
ious 0.060272216796875
▁and 2.4921875
▁evidence 4.578125
- 0.0019054412841796875
based 0.15771484375
▁approach 0.466064453125
. 1.7548828125
▁Only 4.1015625
▁through 1.521484375
▁robust 5.171875
▁scientific 2.23046875
▁validation 5.16796875
▁and 0.90283203125
▁objective 6.57421875
▁evaluation 3.349609375
▁can 0.52392578125
▁the 1.341796875
▁hopes 5.54296875
▁raised 4.8984375
▁by 0.20361328125
▁such 5.484375
▁ground 3.001953125
bre 0.1300048828125
aking 0.0007495880126953125
▁research 2.84765625
▁be 0.207275390625
▁transformed 6.5
▁into 0.00875091552734375
▁genu 5.09765625
ine 0.0743408203125
▁treatment 4.87890625
▁options 1.3115234375
▁that 1.53125
▁extend 7.2734375
▁and 4.66796875
▁improve 0.2176513671875
▁the 0.708984375
▁lives 0.434326171875
▁of 0.0049285888671875
▁cancer 0.96630859375
▁patients 0.02178955078125
▁world 1.93359375
wide 0.003482818603515625
. 0.01512908935546875
